NCT00521222View on ClinicalTrials.gov

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NACompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Asthma
Interventions
DRUG

Fluticasone with salmeterol

Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.

DRUG

Fluticasone HFA

Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.

DRUG

Ipratropium HFA

Primary as-needed rescue medication in all treatment groups

DRUG

Albuterol HFA

Secondary as-needed rescue medication in all treatment groups

Trial Locations (3)

10022

Columbia University Medical Center Eastside, New York

10032

Columbia Presbyterian Medical Center, New York

07601

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Columbia University

OTHER

NCT00521222 - Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes | Biotech Hunter | Biotech Hunter